Literature DB >> 30930184

A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018.

Chioma C Dan-Nwafor1, Oladipupo Ipadeola2, Elizabeth Smout3, Elsie Ilori2, Ayodele Adeyemo4, Chukwuma Umeokonkwo5, Damian Nwidi5, Williams Nwachukwu6, Winifred Ukponu7, Emeka Omabe5, Uchenna Anaebonam8, Nneka Igwenyi5, Gordon Igbodo2, Womi Eteng2, Ikemefule Uzoma2, Muhammed Saleh2, Joseph Agboeze5, Samuel Mutbam8, Tanyth de Gooyer8, Rosie Short8, Everistus Aniaku2, Robinson Onoh5, Emeka Ogah5, Patrick Nguku9, John Oladejo2, Clement Peter8, Olubunmi Ojo2, Chikwe Ihekweazu2.   

Abstract

BACKGROUND: Lassa fever is an acute viral haemorrhagic disease endemic in Nigeria. The 2018 Lassa fever outbreak in Nigeria was unprecedented, with 8% of all cases occurring among healthcare workers (HCWs). A disproportionately high number of these infections occurred in HCWs working in a tertiary health facility in Nigeria. This paper describes the cluster of Lassa fever infections among HCWs in a treatment centre and the lessons learnt.
METHODS: We analysed clinical, epidemiological and laboratory data from surveillance and laboratory records kept during the 2018 outbreak. Interviews were conducted with surviving HCWs using a questionnaire developed specifically for the investigation of Lassa fever infections in HCWs. Descriptive analysis of the data was performed in Microsoft excel.
RESULTS: The index case was a 15-year-old male who presented at the health facility with fever and uncontrolled nasopharyngeal bleeding, following a recent uvulectomy by a traditional healer. Overall, 16 HCWs were affected (15 confirmed and 1 probable) with five deaths (CFR-31.6%). Of the 15 confirmed cases, five (33.3%) were asymptomatic. Nine HCWs were direct contacts of the index case; the remaining six HCWs had no direct contact with the index case. HCW interviews identified a low index of suspicion for Lassa fever leading to inadequate infection prevention and control (IPC) practices as possible contributing factors to nosocomial transmission.
CONCLUSION: Maintaining a high index of suspicion for Lassa fever in all patients, especially in endemic areas, is essential in adhering to adequate IPC practices in health facilities in order to prevent nosocomial transmission of Lassa fever among HCWs. There is a need to continually train and sensitise HCWs on strict adherence to IPC measures while providing care, irrespective of a patient's provisional diagnosis. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Healthcare workers; Lassa fever; Nosocomial infection

Mesh:

Year:  2019        PMID: 30930184     DOI: 10.1016/j.ijid.2019.03.030

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  14 in total

1.  Evaluation of infection prevention and control practices in Lassa fever treatment centers in north-central Nigeria during an ongoing Lassa fever outbreak.

Authors:  Ifeoma Maureen Obionu; Chinwe Lucia Ochu; Winifred Ukponu; Tochi Okwor; Chioma Dan-Nwafor; Elsie Ilori; Chikwe Ihekweazu
Journal:  J Infect Prev       Date:  2021-08-28

2.  Descriptive epidemiology of Lassa fever in Nigeria, 2012-2017.

Authors:  Onyebuchi Augustine Okoro; Eniola Bamgboye; Chioma Dan-Nwafor; Chukwuma Umeokonkwo; Elsie Ilori; Rimamdeyati Yashe; Muhammad Balogun; Patrick Nguku; Chikwe Ihekweazu
Journal:  Pan Afr Med J       Date:  2020-09-03

3.  Bayesian estimation of Lassa virus epidemiological parameters: Implications for spillover prevention using wildlife vaccination.

Authors:  Scott L Nuismer; Christopher H Remien; Andrew J Basinski; Tanner Varrelman; Nathan Layman; Kyle Rosenke; Brian Bird; Michael Jarvis; Peter Barry; Patrick W Hanley; Elisabeth Fichet-Calvet
Journal:  PLoS Negl Trop Dis       Date:  2020-09-21

4.  ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.

Authors:  Robert J Fischer; Jyothi N Purushotham; Neeltje van Doremalen; Sarah Sebastian; Kimberly Meade-White; Kathleen Cordova; Michael Letko; M Jeremiah Matson; Friederike Feldmann; Elaine Haddock; Rachel LaCasse; Greg Saturday; Teresa Lambe; Sarah C Gilbert; Vincent J Munster
Journal:  NPJ Vaccines       Date:  2021-03-02       Impact factor: 7.344

5.  Early onset of neurological features differentiates two outbreaks of Lassa fever in Ebonyi state, Nigeria during 2017-2018.

Authors:  Nneka M Chika-Igwenyi; Rebecca E Harrison; Christina Psarra; Julita Gil-Cuesta; Maria Gulamhusein; Emeka O Onwe; Robinson C Onoh; Uche S Unigwe; Nnennaya A Ajayi; Ugochukwu U Nnadozie; Chiedozie K Ojide; Damian U Nwidi; Obumneme Ezeanosike; Emeka Sampson; Azuka S Adeke; Collins N Ugwu; Uchenna Anebonam; Jacques K Tshiang; Jacob Maikere; Anthony Reid
Journal:  PLoS Negl Trop Dis       Date:  2021-03-08

Review 6.  The niche of One Health approaches in Lassa fever surveillance and control.

Authors:  Liã Bárbara Arruda; Najmul Haider; Ayodeji Olayemi; David Simons; Deborah Ehichioya; Adesola Yinka-Ogunleye; Rashid Ansumana; Margaret J Thomason; Danny Asogun; Chikwe Ihekweazu; Elisabeth Fichet-Calvet; Richard A Kock
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-04-24       Impact factor: 3.944

7.  Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study.

Authors:  Alexandre Duvignaud; Marie Jaspard; Ijeoma Chukwudumebi Etafo; Delphine Gabillard; Béatrice Serra; Chukwuyem Abejegah; Camille le Gal; Abiodun Tolani Abidoye; Mahamadou Doutchi; Sampson Owhin; Benjamin Séri; Jackson Katembo Vihundira; Marion Bérerd-Camara; Justine Schaeffer; Nicolas Danet; Augustin Augier; Ephraim Ogbaini-Emovon; Alex Paddy Salam; Liasu Adeagbo Ahmed; Sophie Duraffour; Peter Horby; Stephan Günther; Akinola Nelson Adedosu; Oladele Oluwafemi Ayodeji; Xavier Anglaret; Denis Malvy
Journal:  Lancet Glob Health       Date:  2021-04       Impact factor: 26.763

8.  Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Authors:  Laura Merson; Josephine Bourner; Sulaiman Jalloh; Astrid Erber; Alex Paddy Salam; Antoine Flahault; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2021-09-21

9.  High crossreactivity of human T cell responses between Lassa virus lineages.

Authors:  Brian M Sullivan; Saori Sakabe; Jessica N Hartnett; Nhi Ngo; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Beatrice Cubitt; Selma D Garcia; Brian C Ware; Dylan Kotliar; Refugio Robles-Sikisaka; Karthik Gangavarapu; Luis Branco; Philomena Eromon; Ikponmwosa Odia; Ephraim Ogbaini-Emovon; Onikepe Folarin; Sylvanus Okogbenin; Peter O Okokhere; Christian Happi; Juan Carlos de la Torre; Pardis C Sabeti; Kristian G Andersen; Robert F Garry; Donald S Grant; John S Schieffelin; Michael B A Oldstone
Journal:  PLoS Pathog       Date:  2020-03-06       Impact factor: 6.823

10.  Impact of Predator Exclusion and Habitat on Seroprevalence of New World Orthohantavirus Harbored by Two Sympatric Rodents within the Interior Atlantic Forest.

Authors:  Briana Spruill-Harrell; Anna Pérez-Umphrey; Leonardo Valdivieso-Torres; Xueyuan Cao; Robert D Owen; Colleen B Jonsson
Journal:  Viruses       Date:  2021-09-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.